spacer
home > ebr > spring 2002 > xenova: managing consolidation and change - a source of competitive advantage for smes?
PUBLICATIONS
European Biopharmaceutical Review

Xenova: Managing Consolidation and Change - A Source of Competitive Advantage for SMEs?

To many external observers, the announcement of the Xenova/Cantab merger in February 2001 came as something of a surprise. Following disappointing trial results with its partnered later stage development product TH-GW, a genital warts vaccine, plus a failed courtship with Peptide Therapeutics (now Acambis plc), Cantab was without a Chief Executive and had indicated it was up for sale. Although the company had a pipeline full of promising and varied early stage biological therapeutics in cancer and vaccines (including ground-breaking anti-addiction vaccines), the negative news flow had impacted the share price, providing something of a bargain to potential acquirers. There was not only a good deal of genuine interest in Cantab from a number of companies, but a good deal of speculation too. Xenova, it seems, was not on many people's radar at the time and initially was not particularly well-received by the financial community as the ultimate acquirer.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Editor of EBR

David Oxlade originally joined Xenova as Chief Executive of Xenova Discovery Limited in June 1997, becoming Group Chief Executive of Xenova Group plc in March 1998. Originally trained as a Biochemist, David spent seven years working for Boehringer Mannheim in the UK before moving into a general management role which included developing commercial operations internationally, specifically in Asia.
He moved to ICI, now AstraZeneca, in 1985 with a specific remit to develop health care business beyond ethical pharmaceuticals, and successfully co-founded the DNA-fingerprinting diagnostic business Cellmark Diagnostics. Prior to joining Xenova, David was President of the US-based Syva Division of Behring Diagnostics Inc (part of Hoeschst AG), formerly part of Syntex.
Dr John St Clair Roberts, Medical Director and an Executive Director of the Xenova Group, became part of the organisation as a result of the merger of Xenova with Cantab Pharmaceuticals plc, where he held similar responsibilities. John originally joined Cantab in 1994 with responsibility for worldwide clinical development, becoming a member of its Executive Board in July 1999.
Prior to Cantab, he had been Medical Director of Pasteur Merieux (UK) where he was responsible for the development of several prophylactic vaccines including a combined measles, mumps and rubella vaccine and a Haemophilus influenzae type b vaccine. John practiced hospital-based medicine prior to joining the pharmaceutical industry in 1986 and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, the Medical Society of London and the Royal Society of Medicine.

spacer
Dr John St Clair Roberts
spacer
spacer
spacer
David Oxlade
spacer
spacer
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AstroNova introduces its range of grass paper labels derived from grass for high quality organic products

Dietzenbach, 29 April 2019, AstroNova GmbH, European headquarters of AstroNova Inc. (RI, USA), responsible for Sales and Customer Service in Europe, the Middle East and Africa (EMEA), is extending its Product Identification range with new approved labelling for direct foodstuff contact.
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement